Report by Blueshift Research
BL
Following interviews with several industry specialists, Blueshift finds ESTA will not reach anywhere near majority market share in the US with its Motiva breast implants and faces scepticism about its minimally invasive augmentation technique. Multiple sources cited Sientra as a cautionary tale: it launched in the US with a strategy similar to ESTA (premium pricing based on claims of improved safety) but has largely given up on its pricing goals and has peaked at about 15% market share. Sources forecast Motiva’s US market share at a similar level.